Gilead Doesn’t Push Limits In Pricing Its New Lymphoma Drug Zydelig
Facing pressure over the price of its hep C treatment Sovaldi, Gilead’s patient assistance program potentially knocks down the monthly copay to $5 for its newly approved idelalisib.
Facing pressure over the price of its hep C treatment Sovaldi, Gilead’s patient assistance program potentially knocks down the monthly copay to $5 for its newly approved idelalisib.